PRESS RELEASES

News: Umeå, 9 August 2022. Lipum (publ), a biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation...
Press release: Umeå, 27 July, 2022. Lipum AB has published the interim report for period January to June 2022. Below is a short summary, a complete...
News: Umeå, 8 July, 2022. Lipum (publ) is preparing for the start of its first in human phase 1 clinical trial and the team is now strengthened with...
Press release: Umeå, 17 June 2022. Lipum (publ) reports that the GLP toxicology- and safety program on the candidate drug (SOL-116) has been completed...
News: Umeå, 25 May 2022. In June, Lipum will present at Redeye Growth Day, EULAR 2022, Biostock Life Science Summit Spring and Aktiespararnas Småbolagsdag...
Press release: Umeå, 18 May 2022. Lipum AB (publ) has published the interim report for period January to March for 2022. Below is a summary, a complete...
News: Umeå, 13 May 2022. Lipum AB (publ) has started a collaboration with Pelago Bioscience AB to strengthen the bioanalytical development for pre-clinical...
Press release: Umeå, 5 May 2022. Lipum AB (publ) is one of the partners contributing to the KKS-Synergy grant application "Drug discovery targeting...
News: Umeå, 7 April 2022. Lipum (publ) reports that the abstract entitled "A Novel Target for Treatment of Inflammatory Joint Diseases"...
Press release: Umeå, 25 March 2022. Lipum AB (publ) has published the interim report for period October to December and the year-end report for 2021...

INVESTOR RELATIONS